Free tool
FAERS Monitor: Durysta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211911 or its brand name (Durysta, Bimatoprost). Reports on generic versions are filed under their own applications.
Reports
2,818
Serious
1,650
59% of reports
Hospitalization
669
Death reported
129
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective268
- intraocular pressure increased113
- ocular hyperaemia108
- no adverse event107
- eye irritation93
- eye pain92
- nausea80
- dyspnoea78
- vision blurred73
- diarrhoea71
- fatigue71
- headache71
- madarosis61
- off label use61
- dizziness57
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 10 |
| 2005 | 4 |
| 2006 | 8 |
| 2007 | 12 |
| 2008 | 21 |
| 2009 | 22 |
| 2010 | 23 |
| 2011 | 36 |
| 2012 | 21 |
| 2013 | 51 |
| 2014 | 65 |
| 2015 | 82 |
| 2016 | 119 |
| 2017 | 207 |
| 2018 | 180 |
| 2019 | 198 |
| 2020 | 237 |
| 2021 | 299 |
| 2022 | 232 |
| 2023 | 299 |
| 2024 | 238 |
| 2025 | 238 |
| 2026 | 216 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,341 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intraocular pressure increasedSignal | 113 | 66.6 | 55.5 | 7,173 |
| madarosisSignal | 61 | 39.4 | 30.7 | 2,236 |
| ocular hyperaemiaSignal | 108 | 17.0 | 14.1 | 1,613 |
| eye painSignal | 92 | 12.2 | 10.0 | 935 |
| eye irritationSignal | 93 | 12.1 | 9.9 | 935 |
| no adverse eventSignal | 107 | 4.4 | 3.7 | 281 |
| vision blurredSignal | 73 | 4.0 | 3.2 | 160 |
| drug ineffective | 268 | 1.5 | 1.4 | 50 |
| dyspnoea | 78 | 1.0 | 0.8 | 0 |
| dizziness | 57 | 0.9 | 0.7 | 1 |
| headache | 71 | 0.8 | 0.7 | 2 |
| diarrhoea | 71 | 0.8 | 0.7 | 3 |
| nausea | 80 | 0.8 | 0.6 | 6 |
| fatigue | 71 | 0.7 | 0.5 | 11 |
| off label use | 61 | 0.5 | 0.4 | 28 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.